<DOC>
	<DOC>NCT01058044</DOC>
	<brief_summary>The purpose of this study is to describe adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor. Moreover, this study is aimed at evaluating the feasibility to use a " Medication Event Monitoring System " (MEMSÂ®) in order to assess adherence of an oral anticancer treatment delivered by dispensary pharmacy.</brief_summary>
	<brief_title>Adherence to Oral Anticancer Treatment Using Electronic Monitoring System</brief_title>
	<detailed_description />
	<criteria>Age &gt; 18 years histologically proven malignant tumor documented decision of treatment with i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an nonsteroidal aromatase inhibitor ambulatory treated subject Subject who accept to use MEMS monitors to automatically compile their drug dosing histories Written informed consent any severe concomitant wich makes it undesirable for the patient to participate in the study or which would jeopardize adherence with trial protocol patient who does not agreed to participate the program</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Cancer, Sunitinib, capecitabine, anastrozole, letrozole</keyword>
	<keyword>adherence, anticancer treatment</keyword>
</DOC>